New hope for rare bleeding disorder: drug trial targets Life-Threatening clot deficiency
NCT ID NCT06963216
First seen Feb 02, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study tests a drug called Coagadex to see if it can safely stop or prevent bleeding in adults with a rare condition where their blood doesn't clot properly. The condition is caused by a disease called AL amyloidosis. About 15 people aged 18 to 70 will receive the drug and be monitored for how well it controls bleeding episodes or bleeding during surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED FACTOR X DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Clinical Trials Unit
RECRUITINGLondon, London, NW1 2PG, United Kingdom
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
Contact
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.